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Summary A series of 1,438 parents and 2,663 other relatives of retinoblastoma patients have been followed
up to ascertain the incidence among them of non-ocular cancer. Among 117 of these relatives who were
known carriers of the mutation of the retinoblastoma gene 23 cases of non-ocular cancer developed during
the follow-up period of the study. This compares with an expected number of 2.3, a relative risk of 9.9. A
total of 25 deaths among these carriers included 21 from non-ocular cancer; the expected number was 1.8, a
relative risk of 11.6. Relatives who are carriers are about 15 times more likely to die from lung cancer than
the general population. Previous findings of an association of melanoma and bladder cancer with
retinoblastoma are borne out in this study. The incidence of non-ocular cancer among relatives of hereditary
cases who are not definitely known to be carriers shows an excess risk of 1.6: it is concluded that a
proportion of these relatives are in fact carriers of the mutated retinoblastoma gene. For relatives who are not
gene carriers there appears to be no excess risk of developing cancer. Carrier relatives who are not themselves
affected with retinoblastoma may be inherently less liable than affected carriers to the further genetic changes
which lead to the development of both retinoblastoma and subsequent non-ocular cancer.
Retinoblastoma is a rare tumour of the retina which occurs
in approximately one in 20,000 live born children. It has a
strong genetic component: about 40% of all cases are
associated with a heritable mutation affecting the long arm
of chromosome 13.
Knudson (1978) suggested that retinoblastoma is caused
by mutational events affecting homologous genes on each of
a pair of chromosomes. In the hereditary form of the disease
one of these mutant genes is inherited; the second mutation
occurs in a somatic cell. Murphree & Benedict (1984)
postulated that the 'wild type' allele Rb+ at the retino-
blastoma locus is a suppressor gene and controls growth: the
mutant gene Rb- at this locus is recessive at the cellular
level and when both genes are mutated or missing, retino-
blastoma will develop.
Recent work in molecular biology has identified the
particular chromosomal area containing the Rb locus;
Friend et al. (1986) identified a segment of chromosome
band 13q 14 which'is frequently deleted in retinoblastoma
and osteosarcoma. Loss or inactivation of the retino-
blastoma gene has also been reported in tumour tissue from
patients with primary breast cancers (Lee et al., 1988) and
small cell lung cancer (Harbour et al., 1988), even though
there is no reason to suppose that these patients had
retinoblastoma.
Patients with the hereditary form of retinoblastoma who
survive after treatment for the disease have a substantially
increased risk of developing a second primary neoplasm, in
particular an osteosarcoma (Draper et al., 1986). The risk
apparently does not affect patients with the non-hereditary
form of retinoblastoma.
It has been suggested that this association of other cancers
with hereditary retinoblastoma can also be manifested in a
generally increased risk of cancer in the relatives of the
patients (Gordon, 1974; Fedrick & Baldwin, 1978; Bonaiti-
Pellie & Briard-Guillemot, 1980; Strong et al., 1984;
Tarkkanen & Karjalainen, 1984; Der Kinderen et al., 1988).
Gordon (1974) suggested that the high proportion of
malignant tumours among relatives might be a consequence
of other expressions of a gene causing retinoblastoma.
Bonaiti-Pellie & Briard-Guillemot (1980) postulated that the
excess of cancer deaths among grandparents of retino-
blastoma patients could be the result of a factor of suscepti-
bility to cancer different from the retinoblastoma gene.
Strong et al. (1984) suggested that an excess of cancer deaths
in relatives may be attributable to an unexpressed retino-
blastoma gene or a precursor of the gene.
Materials and methods
In order to test the hypothesis that there is an increased risk
of non-ocular cancer in relatives of retinoblastoma patients
we have used data from two sources.
The first of these was a survey based on interviews with
parents of children in Britain who developed cancer.
Included in this survey were children who died of retino-
blastoma from 1953 to 1971, surviving children registered
with retinoblastoma from 1962 to 1971 in the national
cancer registration scheme, and all children treated for
retinoblastoma at certain centres in Britain before 1962, and
surviving at least three years from treatment.
The second source of information is a series of interviews
with parents of children born between 1965 and 1985 who
were seen at Moorfields Eye Hospital and St Bartholomew's
Hospital for treatment of retinoblastoma or for follow-up
after treatment. A complete pedigree was obtained for each
index child, including full names and dates ofbirth of parents,
siblings, grandparents, uncles and aunts. Questions were asked
relating to any cancers and other serious illnesses and causes
of death among these relatives. Dates of illness and death
and hospitals of treatment were ascertained to enable us to
verify statements made during the interviews by consulting
medical records, cancer registrations and death certificates.
In the present paper we discuss the occurrence of non-
ocular cancers in the parents, aunts, uncles and grandparents
of children with retinoblastoma. The occurrence of cancer in
the siblings of retinoblastoma patients will be presented in a
separate paper. Standard methods (see, for example, Coleman
et al., 1986) have been used to compare cancer incidence rates
and mortality from cancer and other causes in each group
of relatives with that in the general population. All brain
tumours and malignant neoplasms other than non-melanoma
skin cancers have been included in the analysis. The
observed numbers of cancers were compared with expected
numbers calculated using age-sex-specific incidence rates
based on data from the national cancer registration scheme
for England and Wales, which is estimated to include 90%
of all cancers. Expected numbers of registrations are based
on data for 1968-78. Observed numbers of deaths, both
from cancer and from all other causes, were compared with
expected numbers calculated using age-sex-specific mortality
rates for England and Wales in the appropriate 5-year
calendar periods.
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In calculating the observed and expected numbers of
deaths among mothers we have taken the period at risk as
starting at the time of birth of the child. The rationale for
this is that the study group is established only at this time:
deaths can only be observed after the birth of the child and
expected numbers must be calculated on the same basis. The
same rule was used for fathers: it might be argued that their
period of risk should start at conception but provided that
both expected and observed deaths are calculated from the
same starting point a valid estimate of the relative risk is
obtained. The same reasoning has been applied to the
comparison of observed and expected numbers of cancer
registrations; although it is possible that a parent may
develop cancer before the birth of the index child, it seems
likely that a person with cancer has a reduced chance of
parenthood and thus the observed number of cancers
occurring before the index children are born is likely to
underestimate the true rate. Using similar reasoning the
period of risk for paternal/maternal grandparents is taken to
start at the date of birth of the father/mother. For aunts and
uncles the period of risk is taken to start at age 1 year, since
there is evidence in this study that deaths in infancy among
these relatives were not fully reported. All relatives were
assumed to be at risk until the effective date of follow-up
defined below.
The increased incidence of, or mortality from, cancer is
measured here by the ratio of observed to expected cases,
which gives an estimate of the relative risk (averaged over
different ages) of cancer occurring in these relatives as
compared with the general population. Confidence limits for
this relative risk have been calculated where appropriate by
regarding the expected number of cases as a fixed quantity
and the observed number as having a Poisson distribution.
Cancer in parents of retinoblastoma patients
We were able to obtain sufficient identifying information
about 706 fathers and 732 mothers of retinoblastoma
patients in the above studies for them to be notified to the
National Health Service Central Registers (NHSCR) for
'flagging'. The NHSCR routinely receives copies of all death
certificates for patients and cancer registrations from 1971
onwards. As a result of this we have been informed of all
deaths among the parents up to the end of 1986 and cancer
registrations from 1971 to the end of 1984. (It is estimated
that for 1984 more than 90% of cancers included in the
national cancer registration scheme had been notified to the
NHSCR by the time we analysed the results; for earlier years
the proportion was much higher.) The effective date of
follow-up for parents has therefore been taken as the end of
1984 for cancer registrations and the end of 1986 for deaths.
For parents notified to us as having emigrated, the date at
which they are lost to follow-up is taken as the date of
emigration.
Parents of affected children were divided into three groups
according to the likelihood that they were carriers of the
mutation at the Rb locus. Known 'carriers' included those
parents who had themselves had retinoblastoma or who had
affected relatives in their own or a previous generation.
'Possible carriers' included parents of children with bilateral
tumours and parents of more than one child with retino-
blastoma. 'Probable non-carriers' consisted of parents of
children with unilateral tumours and no known family
history of the disease and of parents whose spouses were
known carriers.
For each group the observed number of cancer
registrations for all types of cancer together was compared
with the expected number calculated as described above.
For the group of parents who were carriers of the
retinoblastoma gene, observed and expected numbers were
also compared separately for lung cancer, breast cancer,
bladder cancer, brain tumours and melanoma.
In this part of the study all non-ocular cancer has been
documented by cancer registrations and death certificates.
Cancer in grandparents, uncles and aunts of retinoblastoma
patients
Information about other relatives was obtained from the
pedigree study of patients at Moorfields and St
Bartholomew's Hospitals described above. This included
families of 316 survivors from retinoblastoma born between
1965 and 1985. All reports of cancer among grandparents,
uncles and aunts of the index child have been followed up,
as have reports of deaths from causes such as pneumonia or
bronchitis which might be indicative of an underlying cancer.
Cancer registrations, medical records and death certificates
have been obtained wherever possible for patients with
cancer and those whose reported deaths came into these
categories. For grandparents, medical documentation has
been obtained for 81% of the reported cancers and for 86%
of reported deaths from cancer. The equivalent figures for
aunts and uncles are 92% and 100%.
Information about infant deaths among siblings of the
interviewed parents was not complete; therefore observed
and expected deaths under the age of 1 year among uncles
and aunts have been excluded from the analysis.
Death certificates have not been obtained for reported
deaths from specific non-cancer causes. During the
interviews parents were frequently unable to give sufficiently
accurate identifying information about these events.
For the analysis of reported cancers, the 'best possible'
diagnosis has been used. The diagnosis was taken firstly
from medical records. If these were not available, the
diagnosis was taken from the cancer registration; otherwise a
diagnosis based on the interview statement about cancer was
used. Similarly, with deaths from all causes and deaths from
cancer the diagnosis on the death certificate if available was
used in the analysis; the cause of death stated in the
interview was used if information given by the parent was
inadequate to obtain a death certificate. The effective date of
follow-up for these relatives if no cancer or death had
occurred was taken to be the date of the interview or the last
date each relative was known to be alive.
The relatives have been grouped according to the likeli-
hood that they were carriers of the mutation at the Rb locus,
but different criteria have been used than those for the study
of the parents. For some relatives it is clear that they are
carriers of the retinoblastoma gene, either because they have
actually had the disease or because of the pattern of
occurrence in the rest of the family (group 1, see Appendix).
For the remaining relatives we have assessed the likelihood
of their being carriers using criteria explained in the
Appendix and illustrated in Figure 1. For the 64 families
where there is more than one case of retinoblastoma (i.e. at
least one case in addition to the index child) relatives not in
group 1 have been classified as group 2, with a probability
of 50% of carrying the gene, or as groups 3 or 4 in order of
decreasing probability. Relatives are categorised as probably
not a carrier in all families where there is only one individual
with retinoblastoma; this is subdivided into families where
the index child had bilateral tumours (group 5), and those
where the tumour was unilateral (group 6). Where there is a
family history of retinoblastoma on the other side of the
family, relatives are categorised as group 7.
Expected numbers of cancers and deaths were calculated
using methods described above.
Results
Table I gives the total numbers of relatives of retinoblastoma
patients included in this study. Moorfields Eye Hospital and
St Bartholomew's Hospital are centres of referral for
children with retinoblastoma from other hospitals in Britain,
especially for bilateral cases and those with a known family
history of the disease, and thus there is a higher proportion
of bilateral cases in the study of cancer in grandparents,
uncles and aunts, than in the study of cancer in parents.360 B.M. SANDERS et al.
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Figure 1 Pedigrees illustrating relatives categorised according to likelihood ofbeing a carrier of the mutation at the Rb locus (see
Appendix). Numbers indicate subdivision into groups.
Table 1 Numbers of relatives included in study
Laterality of retinoblastoma in index child
No record of
Relatives Unilateral Bilateral laterality Total
Fathers 380 317 9 706
Mothers 396 327 9 732
Paternal grandfathers 124 174 - 298
grandmothers 124 173 - 297
uncles 148 254 - 402
aunts 133 208 - 341
Maternal grandfathers 130 177 - 307
grandmothers 130 177 - 307
uncles 169 186 - 356
aunts 159 197 - 355
Total number of relatives 1,893 2,190 18 4,101
Cancer in parents of retinoblastoma patients
A total of 1,415 (98.4%) parents of patients with retino-
blastoma have been flagged at the NHSCR; for the
remaining 23 included in Table I a follow-up date is
available from interview information. Table II shows the
observed and expected numbers of cancer registrations, of
deaths from all cancers and of deaths from all other causes
for parents grouped according to the likelihood that they
were carriers of the mutation at the Rb locus, as explained
above. Parents who developed cancer before the birth of the
index child have been excluded from the analyses. Parents
whose children were born in 1985 have been excluded from
the analysis of cancer registrations but included in the
analysis of deaths.
As would be expected, and in accord with previous
published findings, parents who were carriers have a greatly
increased risk of developing cancer in adult life. The risk is
13 times as great both for cancer registrations and for deaths
from cancer as compared with the general population. (The
95% confidence limits for this relative risk are 7.1 and 21.7
for registrations, 6.7 and 22.7 for deaths).
The 14 registered cases of non-ocular cancer included in
the analysis all developed among 70 parents who had
themselves been affected with retinoblastoma. Among 19
parents not affected but known to be carriers of the
retinoblastoma gene, there were no subsequent cases of non-
ocular cancer.
For the possible carrier group where the index child has
hereditary retinoblastoma and it is not known whether this is
a new mutation or, if an inherited risk, which parent is the
carrier, the risk of developing another cancer is 1.5 times
that of the general population (95% confidence limits 0.9
and 2.4). For probable non-carriers there is no increased risk
compared with the general population.
The low ratio (0.6) of observed to expected deaths from
causes other than cancer among the probable non-carrier
group of parents may be at least partly a 'healthy parent'
effect (see Discussion).
Table III lists the cancer registrations and deaths from
cancer among carrier parents included in the analyses. For
this group the ratios of observed to expected cancers have
been calculated for separate neoplasms and the results are
given in Table IV. For each group, with the exception of
breast cancer, the observed numbers are significantly greater
than the expected numbers (P<0.05 in each case).
Previous studies have suggested that there is a raised
incidence of certain tumours in retinoblastoma survivors. In
the younger age groups there is a particularly high risk of
osteosarcomas and soft tissue sarcomas. Cancers reported in
older survivors include melanoma, brain tumours and
bladder cancer. Table IV shows that although the numbers
of these tumours observed among carriers in the present
study are small, they are greatly in excess of expectation.
In addition to the cases of cancer included in the above
analysis, cancer registrations or death certificates were
received for a further 22 parents. These have had to be
excluded from the analysis because they did not fulfil the
strict criteria for inclusion (registrations of malignant neo-
plasms or brain tumours after the birth of the index child,
after the beginning of 1971 and before the end of 1984; and
deaths before the end of 1986).
=
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Table II Observed and expected numbers of cancers and deaths from other causes among parents of retinoblastoma patients
Cancer registrations Deaths from cancer Deaths from other causes
Study Total OIE Total OIE
group in group Observed Expected (95% Ci)' in group Observed Expected (95% CI)a Observed Expected OIE
Carrier 89 14 1.1 13.0 97 12 0.9 13.0 2 1.9 1.0
(7.1-21.7) (6.7-22.7)
Possible 464 17 11.4 1.5 502 16 11.6 1.4 21 24.2 0.9
carrier (0.9-2.4) (0.8-2.2)
Probable 801 24 22.9 1.0 839 19 22.9 0.8 29 48.4 0.6
non- (0.7-1.6) (0.5-1.3)
carrier
'95% confidence interval for ratio OIE.
Table III Non-ocular neoplasms in 'carrier' parents included in the analyses of cancer
registrations and death certificates
Non-ocular neoplasm
Retinoblastoma Cancer registration Death certificate
laterality Diagnosis age (years) age (years)
Fathers
Unilateral Cancer lung 45 45
Bilateral Cancer oesophagus 62 64
Bilateral Cancer lung 34 35
Bilateral Glioma 44 44
Bilateral Glioma 34 34
Unilaterala Cancer lung - 48
Mothers
Unilateral Cancer intestine 43 44
Bilateral Cancer lung 41 41
Unilateral Leiomyosarcoma 41 45
Bilateral Melanoma 42 42
Bilateral Cancer bladder 45 46
Bilateral Cancer ovary 30 32
Unilateralb Cancer breast 41
Bilateralb Melanoma 31
Unilateralb Meningioma 40
aIncluded in death analysis, not in cancer registration analysis; bIncluded in cancer
registration analysis, not in death analysis.
Table IV Observed and expected numbers of cancer registrations and deaths from cancer among parents who are
carriers of retinoblastoma, divided by type of neoplasm
Cancer registrations Deaths from cancer
Type of neoplasm Observed Expected OIE Observed Expected OIE
Respiratory (lung and bronchus) 3 0.18 16.4 4 0.20 19.7
Melanoma 2 0.03a 73.3 1 0.02 55.6
Breast cancer 1 0.25 4.1 0 0.14 -
Bladder cancer 1 0.03 28.8 1 0.01 71.7
Brain tumours (including non-malignant) 3 0.04 73.7 2 0.05 37.9
For each group, with the exception of breast cancer, the observed numbers are significantly greater than the
expected numbers (P<0.05 in each case).
aThe use of 1968-78 registration data leads to some underestimate in the expected number for melanoma.
Table V lists the 16 parents among the carrier and possible
carrier groups who have had to be excluded, and the reasons
for exclusion.
In view of the association between retinoblastoma and
melanoma it should be noted that in addition to the two
mothers who were carriers and developed malignant
melanoma and were included in the analysis, two other
carrier mothers also developed malignant melanoma. One
was successfully treated before the birth of the index child
and the second mother developed melanoma after the end of
the study date.
Another tumour which has been associated with retino-
blastoma is bladder cancer. One mother who was a carrier of
retinoblastoma died of bladder cancer and has been included
in the analysis. In addition a mother who was a possible
carrier died of bladder cancer after the end of the study date,
and a father included in the analysis who was said to have
had a congenital cataract, but is not included among the
carriers of retinoblastoma for lack of precise information,
also died of bladder cancer.
Cancer in grandparents, uncles and aunts of retinoblastoma
patients
Three hundred and sixteen families have been included in the
study of cancers in grandparents, uncles and aunts, and in 64
of these families there has been more than one case of
retinoblastoma. A total of 2,663 of these relatives were
identified in the course of the interviews and follow-up
information obtained up to the date of the interview for
nearly 99% of them. A small number of cases are excluded
from the analysis because the information available for them
lies outside the appropriate period of risk.
Table VI gives the ratios of observed to expected numbers
of reported cancers, deaths from cancer and deaths from
causes other than cancer for grandparents, uncles and aunts362 B.M. SANDERS et al.
Table V Non-ocular neoplasms in 'carrier' and 'possible carrier' parents excluded from the
analyses of cancer registrations and death certificates
Age at
diagnosis
Diagnosis (years) Reason for exclusion
Mothers
Carriers
Squamous cell carcinoma, (skin), 52 1st: diagnostic type not included
died carcinoma lung 2nd: died after end of study date
Carcinoma lung and
carcinoma of breast 39 After end of study date
Melanoma 39 After end of study date
Melanoma 18 Before birth of index child
Fibrosarcoma 18 Before birth of index child
Possible carriers
Cancer of bladder 45 After end of study date
Carcinoma-in-situ cervix 24 Diagnostic type not included
Cancer of breast 42 After end of study date
Squamous cell carcinoma cervix 27 Diagnostic type not included
Fathers
Possible carriers
Basal cell carcinoma 62 After end of study date
Lymphoma 47 After end of study date
Cancer rectum 55 After end of study date
Cancer colon 52 After end of study date
Carcinoma lung 65 After end of study date
Carcinoma lung 62 After end of study date
Carcinoma stomach 78 After end of study date
Table VI Observed and expected numbers of cancers and deaths from other causes among relatives of retinoblastoma patients
Reported cancer Deaths from cancer Deaths from other causes
Total
in group Observed Expected OIE Observed Expected OIE Observed Expected OIE
Grandparents
Group 1 15 9 1.1 8.3 9 0.8 11.3 1 2.1 0.5
2 10 3 1.2 2.4 2 0.9 2.1 2 2.4 0.8
3 74 15 8.9 1.7 12 6.5 1.8 15 17.1 0.9
4 10 5 1.2 4.1 4 1.0 4.0 3 3.2 0.9
5 511 50 61.1 0.8 43 45.4 0.9 116 115.4 1.0
6 453 35 57.5 0.6 26 43.2 0.6 103 106.6 1.0
7 123 8 17.0 0.5 4 13.0 0.3 24 32.8 0.7
Total 1,196 125 148.0 0.8 100 110.8 0.9 264 279.5 0.9
Aunts and uncles
Group 1 15 2 0.2 11.1 2 0.1 22.2 1 0.3 3.2
2 18 - 0.2 - - 0.1 - 1 0.5 2.1
3 65 2 1.1 1.8 1 0.7 1.5 1 2.0 0.5
4 18 - 0.8 - - 0.5 - - 1.0 -
5 653 7 9.9 0.7 6 5.3 1.1 12 14.5 0.8
6 531 2 6.4 0.3 - 3.4 - 7 10.0 0.7
7 120 - 1.6 - - 0.8 - 3 2.5 1.2
Total 1,420 13 20.2 0.6 9 10.8 0.8 25 30.7 0.8
TableVII Observed and expected numbers of cancers and deaths from other causes among 'carrier', 'possible carrier' and other relatives of
retinoblastoma patients
Reported cancer Deaths from cancer Deaths from other causes
Total OIE OIE
in group Observed Expected (95% CI)' Observed Expected (95%CI)a Observed Expected O/E
Grandparents
Carriers 15 9 1.1 8.3 9 0.8 11.2 1 2.1 0.5
(3.8-15.8) (5.1-21.2)
Possible 94 23 11.4 2.0 18 8.4 2.1 20 22.7 0.9
carriers (1.3-3.0) (1.3-3.4)
Probable 1,087 93 135.5 0.7 73 101.6 0.7 243 254.8 1.0
non-carriers (0.6-0.8) (0.6-0.9)
Aunts and uncles
Carriers 15 2 0.2 11.1 2 0.1 22.2 1 0.3 3.3
(1.3-40.1) (2.7-80.2)
Possible 101 2 2.1 1.0 1 1.3 0.8 2 3.4 0.6
carriers (0.1-2.5) (0.0-4.4)
Probable 1,304 9 17.9 0.5 6 9.5 0.6 22 26.9 0.8
non-carriers (0.2-1.0) (0.2-1.4)
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of the index child, subdivded according to the likelihood of
being a retinoblastoma carrier as explained in the Methods
section. As with the parents of retinoblastoma patients the
relatives have then been grouped into three categories:
carriers, possible carriers and probable non-carriers. Ratios
of observed to expected numbers are given in Table VII. The
non-ocular neoplasms among relatives who are carriers of
the retinoblastoma gene are listed in Table VIII. Grand-
parents who were carriers have a risk eight times as great as
expected of developing cancer, and 11 times as great as
expected of dying from cancer (the 95% confidence limits for
these ratios of observed to expected numbers are 3.8 and
15.8, 5.1 and 21.2). Grandparents who were possible carriers
have twice the expected risk of developing cancer and dying
from cancer (95% confidence limits 1.3 and 3.0, 1.3 and 3.4).
The small numbers of observed cancers and deaths from
cancer among uncles and aunts who were carriers or possible
carriers give wide confidence limits for the ratios, though
there is a significant excess of cancer in the carrier group.
The deficit of cancers observed among the relatives who are
probable non-carriers may be a result of incomplete
reporting of cancers and deaths or of misclassification of
causes of death in cases where medical records or death
certificates were not obtained.
The great majority of children in the hospital-based
pedigree study were accompanied by their mothers and a
comparison of the information provided about maternal and
paternal relatives disclosed a generally higher reported
incidence of cancers and deaths among maternal than among
paternal relatives, particularly among the uncles and aunts.
However, the general conclusions are unaffected by this
slight bias.
There may have been a certain degree of under-reporting
of events, particularly among paternal relatives, and it is
possible that the excess risks are higher than quoted here.
Table VIII Non-ocular neoplasms in 'carrier' relatives included in
the analyses of cancers and deaths from cancer
Non-ocular neoplasm
Retinoblastoma Age at diagnosis
laterality Diagnosis (years)
Grandfathers
No record Cancer bladder 63
Unaffecteda Cancer colon 77
Unilateral Cancer lung 45
Bilateral Cancer lung 52
Bilateral Spindle cell sarcoma 47
Unaffected Cancer lung 44
Grandmothers
Bilateral Cancer lung 41
Unaffected Cancer lung 62
Unilateral Cancer uterus 43
Uncle
Unilaterala Cancer lung 56
Aunt
Bilaterala Cancer ovary 33
aMembers of the same family.
Summary of results for all relatives
A high risk of developing non-ocular neoplasms has been
reported in younger survivors from retinoblastoma and the
results from this study show that this increased risk
continues in older survivors who have become parents and
grandparents.
Combining the results of the two separate analyses, we
find that in a total of 117 relatives of retinoblastoma
patients who were themselves carriers of the mutated retino-
blastoma gene there were 23 cases of non-ocular cancer
compared with an expected number of 2.3, a relative risk of
9.9 (95% confidence limits of 6.3 and 14.9). (The total of
117 relatives is smaller than the totals in Tables II and VI
because two individuals appear twice in the analysis: one as
both mother and grandmother, the second as father and
grandfather. This does not of course affect the results of the
separate analyses.) In a total of 25 deaths from all causes
among relatives, 21 deaths were from non-ocular cancer. The
expected number was 1.8, giving a relative risk of 11.6 (95%
confidence limits of 7.2 and 17.7).
Among the relatives who were possible carriers, there were
42 cases of non-ocular cancer compared with an expected
number of 24.8, giving a relative risk of 1.7. Thirty-five
relatives died of cancer as compared with an expected
number of 21.3, a relative risk of 1.6. This reflects the fact
that this group is a mixture of individuals who are in fact
carriers, and who have an excess risk of developing non-
ocular cancer, together with others who do not have the
Rb- gene and therefore presumably have no increased risk.
Discussion
There have been several studies of non-ocular cancer in
relatives of retinoblastoma patients. Strong et al. (1984), in a
study of 80 families, found a significant excess of cancer
deaths in relatives under the age of 55 and in fathers of the
bilateral retinoblastoma probands, and a modest overall
cancer excess in the total group of relatives of hereditary
cases. Der Kinderen et al. (1988) found four non-ocular
cancers compared with 1.9 expected, among 24 parents of
retinoblastoma patients who were themselves carriers of the
retinoblastoma gene. Two hundred and six unaffected
parents of patients with hereditary retinoblastoma were also
followed up and among this group 23 cancers developed: the
fathers were found to have a relative risk of 8.3 for
pancreatic cancer compared with the general population; no
increased risk was found for other non-ocular cancers.
Winther et al. (1988) followed up 267 parents of retino-
blastoma survivors, and, after excluding five who had been
treated for retinoblastoma, observed 14 cases of non-ocular
cancer, a relative risk of 0.9. Three of the cancers were
malignant melanomas. The parents were not subdivided
according to whether their children had unilateral or
bilateral retinoblastoma.
It is well documented that retinoblastoma survivors are at
a high risk of developing second primary neoplasms
(Abramson et al., 1984; Draper et al., 1986; der Kinderen et
al., 1988; Strong et al., 1984). In adolescence the risk is
particularly high for osteosarcomas. The results of this study
give further evidence that the risk persists through the lives
of the survivors.
These previous studies have mentioned melanoma as being
a second tumour particularly associated with retinoblastoma,
and the four carrier mothers in this study who developed
malignant melanoma between the ages of 18 and 42 bear out
this finding. Two grandmothers of retinoblastoma patients
were also diagnosed as having malignant melanoma, they
were not known to have had retinoblastoma.
There is a high ratio of observed to expected numbers of
deaths from cancer of the lung (15.4) among relatives who
are carriers of the mutated retinoblastoma gene. The total of
eight patients in this analysis of deaths from lung cancer
included four with small cell or oat cell carcinoma and one
with undifferentiated adenocarcinoma. The tumour histology
of the other three patients is not known. Two carrier
mothers excluded from the analysis because their second
tumours developed after the end of the study date also died
of lung cancer: one small cell carcinoma, the other oat cell
carcinoma. (One of these patients had a carcinoma of the
breast in addition to the lung cancer.) Strong et al. (1984)
observed a significant excess of lung cancer in relatives under
55. Harbour et al. (1988) and Yokota et al. (1988) suggested
that inactivation of the Rb gene may be involved in the
development of lung cancers, particularly small cell
carcinoma.364 B.M. SANDERS et al.
Several studies have suggested an association between
retinoblastoma and bladder cancer. Der Kinderen et al.
(1988) observed two transitional cell carcinomas of the
bladder among 24 carrier parents. Tarkkanen & Karialainen
(1984) noted two bladder carcinomas among 19 relatives of
patients with bilateral retinoblastoma. Two relatives in this
study who were carriers and six other relatives of children
with bilateral tumours also died of bladder cancer. Der
Kinderen et al. (1988) also found three pancreatic tumours
among unaffected fathers of children with hereditary retino-
blastoma. In this study we noted that two unaffected parents
and two unaffected grandparents of children with bilateral
tumours died of cancer of the pancreas.
Among parents of retinoblastoma patients included in the
cancer registration analysis there were 89 carriers of the
retinoblastoma gene, of whom 70 had themselves had retino-
blastoma. Non-ocular cancer developed in 20 of these
survivors although the analyses of risks can only take
account of 15, for reasons explained above. It is interesting
that among the 19 carrier parents who had not themselves
had retinoblastoma no non-ocular cancers have so far been
recorded. They are known to be carriers because in addition
to having a child with retinoblastoma, either siblings of their
own, children of siblings or relatives in a previous generation
were affected by retinoblastoma. In one family, three
unaffected brothers all had children with retinoblastoma.
These unaffected carriers appear to be inherently less liable
to the further genetic changes which lead to the development
of both retinoblastoma and subsequent non-ocular cancer.
Matsunaga (1979) postulated a host resistance model
whereby unaffected carriers are inherently resistant to
tumour formation. However, it should be noted that among
four grandparents who were certainly carriers but not
reported to have had retinoblastoma themselves, three
subsequently developed non-ocular cancer.
It is clear that inheritance of the Rb- gene confers
susceptibility to other tumours in later life. This is shown
conclusively in this study among the known carriers of the
gene.
The overall excess of cancer deaths of 1.6 among relatives
who were possible carriers of the retinoblastoma gene agrees
with the findings of Strong et al. (1984) and can be
attributed to the fact that a proportion of these relatives are
also in fact carriers of the gene and have a raised likelihood
of developing cancer in later life, though the risk may be less
than that for carriers who are themselves affected by retino-
blastoma.
When all carriers and possible carriers of the retino-
blastoma gene are excluded from the analysis there is a
lower than average mortality among both parents and other
relatives. We think this may be partly accounted for by
under-reporting of events, both deaths and cancers, and, in
particular, by the implicit assumption that relatives for
whom neither of these events were reported at the interview
were alive and well until that time. As a consequence the
relative risks reported in this paper are likely to be under-
estimated. An alternative explanation that may partly
account for the deficit of deaths among parents is, by
analogy with the 'healthy worker' effect, that members of the
population who become parents are a selected group having
a lower mortality than others in their age group - a 'healthy
parent' effect.
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Appendix
Likelihood that grandparent, uncle or aunt of index child was a carrier of the mutation at the RB locus.
Criteria, in addition to index child having retinoblastoma (RBL)
1. Carrier Grandparent
2. Possible carrier
(where spouse did not have RBL) 50% likelihood
3. Possible carrier
(where spouse did not have RBL)
4. Possible carrier
(where spouse did not have RBL)
5. Probably not a carrier
6. Probably not a carrier
7. Not a carrier
(a) Had RBL, treated or spontaneously
regressed
(b) Any relative in the same or previous
generation had RBL or was a carrier
of RBL
(c) Children by two different spouses
had RBL
Uncle/aunt (a) Had RBL, treated or spontaneously
regressed
(b) Child or grandchild had RBL
Grandparent Child (other than parent of index child)
had RBL or was carrier of RBL
Uncle/aunt (a) Parent had RBL or was a carrier of
RBL
(b) Sib (other than parent of index child)
had RBL or was carrier of RBL
Grandparent Only one child had RBL or was carrier
of RBL
Uncle/aunt Only one sib had RBL or was carrier
of RBL
Grandparent Two or more grandchildren in one family
had RBL (one of these was the index child)
Uncle/aunt Two or more nephews or nieces in one
family had RBL (one of these was the
index child)
Grandparent Only index child had RBL and tumours
were bilateral
Uncle/aunt Only index child had RBL and tumours
were bilateral
Grandparent Only index child had RBL and tumour
was unilateral
Uncle/aunt Only index child had RBL and tumour
was unilateral
Grandparent Family history of RBL on other side
of family
Uncle/aunt Family history of RBL on other side
of family